Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.050
-0.070 (-3.30%)
At close: Nov 20, 2024, 4:00 PM
2.070
+0.020 (0.98%)
After-hours: Nov 20, 2024, 7:24 PM EST
Allogene Therapeutics Employees
As of December 31, 2023, Allogene Therapeutics had 233 total employees, including 232 full-time and 1 part-time employees. The number of employees decreased by 128 or -35.46% compared to the previous year.
Employees
233
Change (1Y)
-128
Growth (1Y)
-35.46%
Revenue / Employee
$185
Profits / Employee
-$1,216,433
Market Cap
429.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Pacific Biosciences of California | 796 |
Quanterix | 441 |
National Research | 435 |
Xeris Biopharma Holdings | 377 |
Rigel Pharmaceuticals | 147 |
Tango Therapeutics | 140 |
Foghorn Therapeutics | 116 |
Korro Bio | 102 |
ALLO News
- 2 days ago - Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewsWire
- 3 days ago - Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - GlobeNewsWire
- 13 days ago - Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 13 days ago - Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS - GlobeNewsWire
- 16 days ago - Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 22 days ago - Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 7 weeks ago - Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity - GuruFocus